These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38287533)

  • 21. In brief: Acalabrutinib (Calquence) for mantle cell lymphoma.
    Med Lett Drugs Ther; 2018 Nov; 60(1559):e184. PubMed ID: 30681658
    [No Abstract]   [Full Text] [Related]  

  • 22. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
    da Cunha-Bang C; Niemann CU
    Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acalabrutinib for adults with mantle cell lymphoma.
    Jurczak W; Długosz-Danecka M; Wang M
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):179-187. PubMed ID: 30638402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
    Lee CS; Rattu MA; Kim SS
    J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review.
    Al-Mansour M
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e1019-e1031. PubMed ID: 36068158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma.
    Ran F; Liu Y; Yu S; Guo K; Tang W; Chen X; Zhao G
    Bioorg Chem; 2020 Jan; 94():103367. PubMed ID: 31685258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.
    Davids MS; Brown JR
    Future Oncol; 2014 May; 10(6):957-67. PubMed ID: 24941982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.
    Lee SC; Shestov AA; Guo L; Zhang Q; Roman JC; Liu X; Wang HY; Pickup S; Nath K; Lu P; Hofbauer S; Mesaros C; Wang YL; Nelson DS; Schuster SJ; Blair IA; Glickson JD; Wasik MA
    Mol Cancer Res; 2019 Jun; 17(6):1365-1377. PubMed ID: 30862686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ibrutinib approved for mantle cell lymphoma.
    Cancer Discov; 2014 Jan; 4(1):OF1. PubMed ID: 24402946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia.
    Hanna KS; Fijalka A; Watson I; Brown O; Ojulu A
    J Oncol Pharm Pract; 2022 Dec; 28(8):1869-1884. PubMed ID: 35635742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of acalabrutinib in patients with mantle cell lymphoma.
    Awan FT; Jurczak W
    Expert Rev Hematol; 2018 Jun; 11(6):495-502. PubMed ID: 29737219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
    Rule S; Chen RW
    Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies.
    Muñoz J; Sarosiek S; Castillo JJ
    Oncologist; 2023 Apr; 28(4):309-318. PubMed ID: 36723874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
    Lionel AC; Gurumurthi A; Fetooh A; Eldaya R; Ahmed S; Iyer SP; Nastoupil LJ; Westin J; Nair R; Fayad L; Malpica L; Tummala S; Flowers C; Neelapu SS; Wang ML; Jain P
    Leuk Lymphoma; 2024 May; 65(5):669-673. PubMed ID: 38248629
    [No Abstract]   [Full Text] [Related]  

  • 36. Ibrutinib in B lymphoid malignancies.
    Smith MR
    Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis.
    Di M; Cui C; Kothari SK; Zeidan AM; Podoltsev NA; Neparidze N; Shallis RM; Wang R; Ma X; Huntington SF
    Blood Adv; 2022 Jun; 6(11):3339-3342. PubMed ID: 35240689
    [No Abstract]   [Full Text] [Related]  

  • 38. A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma.
    Romanchikova N; Strods A; Strazdina J; Strumfs B; Trapencieris P
    Anticancer Res; 2016 Nov; 36(11):6133-6140. PubMed ID: 27793942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Staphylococcus aureus meningitis in a patient with mantle cell lymphoma under treatment with ibrutinib.
    Diamantopoulos PT; Psichogiou M; Pantazatou A; Zervakis K; Rougala N; Giannakopoulou N; Daikos G; Viniou NA
    Ann Hematol; 2017 Jun; 96(6):1049-1050. PubMed ID: 28247056
    [No Abstract]   [Full Text] [Related]  

  • 40. Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.
    Taneja A; Jones J; Pittaluga S; Maric I; Farooqui M; Ahn IE; Wiestner A; Sun C
    Leuk Lymphoma; 2019 Feb; 60(2):519-522. PubMed ID: 29978754
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.